Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Congxin Lunzhi Fang (CXLZF) is a Traditional Chinese Medicine (TCM) herbal formula primarily investigated for its therapeutic potential in treating atherosclerosis and related metabolic disorders. The formula is designed based on the "treating from the heart" (Congxin Lunzhi) theory of TCM. Preclinical studies in ApoE-/- mice have demonstrated that CXLZF significantly reduces atherosclerotic plaque size, enhances plaque stability by increasing collagen content, and lowers serum lipid levels. Additionally, it shows hepatoprotective effects by reducing serum transaminases (ALT and AST) and mitigating liver steatosis. The primary mechanism of action involves the upregulation of Angiotensin-Converting Enzyme 2 (ACE2) protein expression and the downregulation of the adhesion molecule E-selectin, thereby reducing vascular inflammation and protecting endothelial function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Congxin Lunzhi Fang.